Innovative Drug Therapy Offers Hope after Brain Injuries

Dr. Edward Tobinick, founder of the Institute of Neurological Recovery, is the lead author of an observational study in the journal CNS Drugs that provides clinical data supporting the effectiveness of etanercept for improving neurological function following a traumatic brain injury or stroke. The researchers examined 629 individuals treated over a 24 month period. Of the study’s participants, 617 received treatment an average of 42 months after they suffered a stroke and 12 received treatment an average of nearly 10 years following brain injury. The length of time between the event that caused the original injury and the administration of the drug therapy meant the researchers could largely discount spontaneous recovery.

The study focuses on an innovative drug called etanercept, which works by binding to and neutralizing a specific inflammatory molecule called TNF. The drug was delivered to patients using a novel method designed by Dr. Edward Tobinick. The researchers observed many positive effects following the administration of etanercept, including statistically significant improvement in cognition and motor impairment in both the stroke and traumatic brain injury groups.

The findings appear under the title Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury—An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept.


Training Program and Research at INR

Dr. Edward Tobinick holds a medical degree from the University of California, San Diego Medical School, and completed residencies in internal medicine and dermatology at the University of California, Los Angeles. In 2001, Dr. Edward Tobinick founded the Institute of Neurological Recovery (INR). Over the course of a decade Dr. Tobinick and his colleagues have conducted research exploring new methods of treatment for neurological dysfunction.

Much of Dr. Tobinick’s work has involved the off-label use of etanercept, a biotechnology therapeutic that binds and inactivates the cytokine TNF. Dr. Tobinick has shared his findings at medical conferences in the United States and internationally. These include the 3rd International Restauracion Neurologica Conference in Havana, Cuba, and the 7th Annual Alzheimer’s Drug Discovery Conference in New York.

In addition to facilitating the aforementioned research on etanercept, the INR conducts a physician training program. For more than four years, the INR physician training program has instructed doctors from the U.S. and abroad on INR’s off-label anti-TNF methods of treatment. Training sessions are held at INR’s Los Angeles, California, and Boca Raton, Florida, locations, and typically last one to two days. The program may be offered in languages other than English, by special arrangement, to facilitate understanding for all participants. Physicians are instructed in injection methods, clinical evaluation and response, dosing schedules, and relevant physiology and anatomy.

For further information, please see the Sun Sentinel newpaper article at the following link:

and the following published, peer-reviewed article: